Parkinson's Disease/Movement Disorders News

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses the unmet needs among patients with Huntington's disease and the clinicians who treat them.

The first subject has been dosed in a phase 1 clinical trial of an oral proteolysis-targeting chimera protein degrader to treat neurodegenerative diseases, according to the manufacturer.

Nipocalimab met the primary endpoint in a pivotal phase 3 trial in patients with generalized myasthenia gravis, as well as in a phase 2 study in adults with Sjögren’s disease, according to topline results released by Johnson & Johnson.

The FDA has approved a rechargeable deep brain stimulation device with remote programming for individuals living with movement disorders, according to the manufacturer.

A clinical stage biotech company has been awarded a grant for $873,000 by The Michael J. Fox Foundation for Parkinson’s Research to help assess sortilin inhibition in Parkinson’s disease.

Inflammasome Therapeutics announced that the first patient has been dosed in its phase 1 study of K8, a novel dual inflammasome inhibitor for treatment of diabetic macular edema.

A Houston-area biotech company will expand indications of its investigational and proprietary biologic combination therapy beyond amyotrophic lateral sclerosis to include frontotemporal dementia and Parkinson’s disease.

A clinical-stage genetic medicine firm has announced $60 million in Series B financing to support a phase 1/2 clinical trial and advance its lead candidate to treat spinocerebellar ataxia types 1 and 3 as well as Huntington’s disease.

The European Medicines Agency has approved enrollment for a phase 1/2a biomarker study to examine a once-daily, oral, brain penetrant mitochondrial stimulator to treat a range of neurological and neuromuscular conditions.

Vanqua Bio has announced its lead candidate for Parkinson’s disease, a small molecule allosteric activator of glucocerebrosidase, will enter clinical development in the first quarter of 2024.